Randomized, controlled, multi-center phase II study of postoperative enoxaparin treatment for venous thromboembolism prophylaxis in patients undergoing surgery for hepatobiliary-pancreatic malignancies

Go Shinke; Yutaka Takeda; Yoshiaki Ohmura; Shogo Kobayashi; Hiroshi Wada; Osakuni Morimoto; Akira Tomokuni; Junzo Shimizu; Tadafumi Asaoka; Masahiro Tanemura; Takehiro Noda; Yuichiro Doki; Hidetoshi Eguchi

doi:10.1002/ags3.12796

Randomized, controlled, multi-center phase II study of postoperative enoxaparin treatment for venous thromboembolism prophylaxis in patients undergoing surgery for hepatobiliary-pancreatic malignancies

Ann Gastroenterol Surg. 2024 Mar 28;8(5):868-876. doi: 10.1002/ags3.12796. eCollection 2024 Sep.

Authors

Affiliations

¹ Department of Surgery Kansai Rosai Hospital Amagasaki Hyogo Japan.
² Department of Gastroenterological Surgery Osaka University Suita Osaka Japan.
³ Department of Surgery JCHO Osaka Hospital Osaka Japan.
⁴ Department of Gastroenterological Surgery Osaka General Medical Center Osaka Japan.
⁵ Department of Surgery Toyonaka Municipal Hospital Toyonaka Osaka Japan.
⁶ Department of Gastroenterological Surgery Osaka Police Hospital Osaka Japan.
⁷ Department of Surgery Rinku General Medical Center Izumisano Osaka Japan.

Abstract

Purpose: Postoperative venous thromboembolism (VTE) risk is pronounced after abdominal cancer surgery. Enoxaparin shows promise in preventing VTE in gastrointestinal, gynecological, and urological cancers, but its application after surgery for hepatobiliary-pancreatic malignancy has been under-evaluated due to bleeding concerns. We confirmed the safety of enoxaparin administration in patients undergoing curative hepatobiliary-pancreatic surgery for malignancies in a prospective, multi-center, phase I study.

Methods: The study was conducted from April 2015 to May 2021 across eight specialized centers. Patients (n = 262) were randomized to enoxaparin prophylaxis given postoperatively for 8 days (n = 131) or control (n = 131). The primary endpoint was the efficacy in reducing VTE. Secondary endpoints examined safety.

Results: The full analysis set included 259 patients (131 control, 129 enoxaparin). The per-protocol population included 233 patients (117 control, 116 enoxaparin). Most cases were hepatic malignancies (111 control, 111 enoxaparin). The median administration duration of enoxaparin was 7 days, with 92% receiving 4000 units/day. Despite a reduction in the relative risk (RR) of VTE due to postoperative enoxaparin administration, the results were not significant (control: four cases, 3.4% vs. treatment: two cases, 1.7%; RR 0.50, 95% CI 0.09-2.70; p = 0.6834). No significant difference was found in the incidence of bleeding events (control: five cases, 4.3% vs. treatment: five cases, 4.3%, RR 1.00, 95% CI 0.53-1.89; p = 1.0000).

Conclusions: The perioperative administration of enoxaparin in hepatobiliary-pancreatic malignancies is feasible and safe. However, further case accumulation and investigation are necessary to assess its potential in reducing the occurrence of VTE.

Keywords: DVT; PTE; VTE prophylaxis; enoxaparin; hepatobiliary‐pancreatic malignancy.